无创评估肝纤维化逆转研究进展*

doi:10.3969/j.issn.1672-5069.2025.02.003

摘要/Abstract

Key words: Chronic liver diseases, Liver fibrosis, Non-invasive assessment, Reverse

朱亭亭, 陈逸云, 谢帆慈, 李正鑫. 无创评估肝纤维化逆转研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 169-172.

Zhu Tingting, Chen Yiyun, Xie Fanci, et al. Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2025, 28(2): 169-172.

[1] Maeso-Díaz R, Gracia-Sancho J. Aging andchronic liver disease. Semin Liver Dis, 2020,40(4):373-384.
[2] Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med, 2011,25(2):169-186.
[3] Franchis R. Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63(3):743-752.
[4] Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology, 2009,49(3):1017-1044.
[5] 刘天会.肝纤维化和肝硬化逆转的血清学评价.临床肝胆病杂志,2019,35(4):714-719.
[6] Karsdal MA, Hjuler ST, Luo Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am J Physiol Gastrointest Liver Physiol, 2019,316(1):G25-31.
[7] Ito K, Murotani K, Nakade Y, et al. SerumWisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol, 2017,32(12):1922-1930.
[8] Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribundaagglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol, 2015,110(6):857-864.
[9] Nielsen MJ, Karsdal MA, Kazankov K, et al. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Aliment Pharmacol Ther, 2016,44(11-12):1242-1252.
[10] Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 2016,64(4):773-780.
[11] Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med, 2018,18(2):273-282.
[12] Stasi C, Salomoni E, Arena U, et al. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment:a preliminary study, Eur J Pharmacol, 2017,806(7):105-109.
[13] Poynard T, McHutchison J, Manns M,et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology, 2003,38(2):481-492.
[14] Tanwar S, Trembling PM, Hogan BJ, et al. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol, 2017,29(3):289-296.
[15] D'Ambrosio R, Degasperi E, Aghemo A, et al. Serologicaltests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. PLoS One, 2016,11(6):e0155967.
[16] Smith AD, Porter KK, Elkassem AA,et al. Current imaging techniques for noninvasive staging of hepatic fibrosis. AJR, 2019,213(1):77-89.
[17] 陈永鹏, 梁携儿. 肝纤维化和肝硬化逆转的影像学评价. 临床肝胆病杂志, 2019,35(4):720-723.
[18] Horowitz JM, Venkatesh SK, Ehman RL, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY), 2017,42(8):2037-2053.
[19] Tang A, Cloutier G, Szeverenyi NM,et al. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR, 2015,205(1):22-32.
[20] Barr RG, Ferraioli G, Palmeri ML, et al. Elastographyassessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement. Ultrasound Q, 2016,32(2):94-107.
[21] Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut, 2007,56(7):968-973.
[22] Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int, 2013,7(2):356-368.
[23] 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版). 中华肝脏病杂志, 2019,27(3):10.
[24] Enomoto M, Mori M, Ogawa T, et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B:regression of liver stiffness during entecavir therapy. Hepatol Res, 2010,40(9):853-861.
[25] Kim SU, Park JY, Kim DY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int, 2010,4(4):673-680.
[26] Ogawa E, Furusyo N, Murata M, et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res, 2011,41(12):1178-1188.
[27] Fung J, Lai CL, Cheng C, et al. Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Am J Gastroenterol, 2011,106(3):492-496.
[28] Yan LB, Zhu X, Bai L, et al. Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy. Hepatol Res, 2013,43(2):185-191.
[29] GL W, VW W, PC C, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther, 2011,16(2):165-172.
[30] Liang X, Xie Q, Tan D, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy:a 2-year prospective study. J Viral Hepat, 2018,25(3):296-305.
[31] Zeng J, Cai S, Liu J, et al. Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B. J Ultrasound Med, 2017,36(2):261-268.
[32] Sun J, Li Y, Sun X,et al. Dynamic changes of the aspartate aminotransferase-to-platelet ratio and transient elastography in predicting a histologic response in patients with chronic hepatitis B after entecavir treatment. J Ultrasound Med, 2019,38(6):1441-1448.
[33] Dong XQ, Wu Z, Li J,et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: a 78-week prospective study. J Gastroenterol Hepatol, 2019,34(4):755-763.
[34] Kong Y, Sun Y, Zhou J,et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat, 2019,26(5):576-585.
[35] Ji D, Chen Y, Shang Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol, 2021,116(8):1676-1685.
[36] Li Z, Zhu T, Zhao Z, et al. Changing liver stiffness predict regression in advanced fibrosis patients with chronic hepatitis B, but not in moderate fibrosis patients. Gastroenterol Hepatol Res, 2023,5(1):13-18.
[37] Xu W, Hu Q, Chen C,et al. Non-invasive assessment of liver fibrosis regression in patients with chronic hepatitis B: a retrospective cohort study. Infect Dis Ther, 2023,12(2):487-498.
[38] Apichet S, Paweenuch S. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment. Medicine (Baltimore), 2024, 103(19):e38096.
[39] Hariklia K, Konstantinos Z, Theodora O,et al. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. a retrospective - prospective multicenter study. BMC Gastroenterol, 2024,24(1):133.
[40] EASL-ALEHclinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol,2015,63(1):237-264.
[41] Archer AJ, Belfield KJ, Orr JG,et al. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol, 2022,13(5):436-439.
[42] Branchi F, Conti CB, Baccarin A, et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol, 2014,20(40):14568-14580.
[43] Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010,52(3):886-893.
[44] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int, 2015,35 (Suppl 1):78-81.
[45] Li ZB, Li L, Niu XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021,41(6):1254-1264.
[46] Yijun M, Cheng P, Huijun C,et al. Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Rev Esp Enferm Dig, 2024,116(8):416-422.
[47] Yin M, Venkatesh SK. Ultrasound or MR elastography of liver: which one shall I use? Abdom Radiol (NY), 2018,43(7):1546-1551.
[48] Venkatesh SK, Talwalkar JA. When and how to use magnetic resonance elastography for patients with liver disease in clinical practice. Am J Gastroenterol, 2018,113(7):923-926.
[49] Guo Y, Parthasarathy S, Goyal P,et al. Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. Abdom Imaging, 2015,40(4):818-834.
[50] Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005,128(2):343-350.
[51] Gheorghe G, Bungău S, Ceobanu G, et al. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc, 2021,120(2):794-803.
[52] Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol, 2015,13(3):440-451,e6.
[53] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep, 2020,2(2):100067.

无创评估肝纤维化逆转研究进展^*

Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	余锴, 梅云华, 周金容, 程正银. 超声瞬时弹性成像诊断慢性乙型肝炎合并脂肪肝患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 190-193.
[2]	朱帝文, 张媛, 鲍应军, 顾俊鹏, 孙丽华, 任伟新. 经颈静脉穿刺肝组织活检操作要点及并发症分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 290-293.
[3]	王常鹤, 朱璇, 邓静, 张聪颖, 赵宇, 刘芳. 超声剪切波弹性成像联合AAR、APRI和FIB-4指数诊断慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 32-35.
[4]	胡雨, 王静晖, 王瑶. 声触诊组织量化技术联合FIB-4指数和AST/ALT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 36-39.
[5]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[6]	马敏, 许巧云. 非酒精性脂肪性肝病患者血清Arg-1水平和ApoB/ApoA1比值变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 52-55.
[7]	叶鹏, 杨本场, 茅明. 恩替卡韦治疗代偿期乙型肝炎肝硬化初治患者远期组织学改善研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 96-99.
[8]	姜社甜, 闫卫, 赵磊, 胡园园, 郭蕾, 魏亚睿. 声触诊组织量化技术联合血清肝纤维化指标诊断肝血吸虫病患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 124-127.
[9]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.
[10]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[11]	唐敏, 曾理, 杨鑫荣. FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 887-890.
[12]	任艳, 孔明, 徐曼曼, 白丽, 陈煜. 瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 725-728.
[13]	信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.
[14]	连作勤, 王世明, 张甲, 李付平. 富马酸丙酚替诺福韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效和安全性评估^*[J]. 实用肝脏病杂志, 2024, 27(5): 753-756.
[15]	汤泽宇, 顾菲, 周健文, 姜小兰, 毛雨婧, 樊琦. CT参数联合FIB-4和血清VEGF水平预测乙型肝炎肝硬化患者并发食管静脉曲张效能分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 579-582.